Skip to Content

Emergency Drug Syringes

Last Updated: August 5, 2010
Status: Discontinued

Products Affected - Description

Amphastar / IMS Syringe Products
Atropine Sulfate Injection 1 mg/10 mL - discontinued
Min-I-Jet (NDC 00548-1039-00) - discontinued
Stick-Gard (NDC 00548-2039-00) - discontinued

Calcium Chloride Injection 10%
10 mL Min-I-Jet (NDC 00548-1004-00) - discontinued
10 mL Stick-Gard (NDC 00548-2004-00) - discontinued

Dextrose Injection 25%
10 mL Luer-Jet (NDC 00548-3304-00) - discontinued

Dextrose Injection 50%
50 mL Min-I-Jet (NDC 00548-1001-00) - discontinued
50 mL Stick-Gard (NDC 00548-2001-00) - discontinued

Epinephrine Injection 1:10,000
10 mL Min-I-Jet (NDC 00548-1016-00) - discontinued
10 mL Stick-Gard (NDC 00548-2016-00) - discontinued

Lidocaine Hydrochloride Injection 2%
5 mL Min-I-Jet (NDC 00548-1190-00) - discontinued
5 mL Stick-Gard (NDC 00548-2190-00) - discontinued

Sodium Bicarbonate Injection 4.2%
10 mL Luer-Jet (NDC 00548-3304-00) - discontinued

Sodium Bicarbonate Injection 8.4%
50 mL Min-I-Jet (NDC 00548-1052-00) - discontinued
50 mL Stick-Gard (NDC 00548-2052-00) - discontinued

Morphine Sulfate Injection 100 mg/4 mL
Dilute-A-Jet (NDC 00548-6045-25) - discontinued

Morphine Sulfate Injection 1 mg/mL
10 mL Stick-Gard (NDC 00548-2901-25) - discontinued
30 mL PCA Syringe (NDC 00548-1931-10) - discontinued

Reason for the Shortage

  • Amphastar / IMS discontinued many emergency drug syringe products because they are unapproved drugs. The company has made a business decision not to file a New Drug Application or Abbreviated New Drug Application for these products.1
  • Hospira is aware of this discontinuation and can supply the market. Hospira does not anticipate any shortages of their emergency drug syringe products.2

Estimated Resupply Dates

Amphastar / IMS has discontinued many of their emergency drug syringe products. Several emergency syringes will be relaunched through the remainder of 2010.1,3

Safety

  • Clinicians must be aware that alternative syringe products may look different than Amphastar / IMS syringes. 
  • Before stocking alternative syringe products, clinicians should ensure compatibility with the available IV solution sets.
  • Extra care should be taken to ensure the same concentrations and salts are used if products are substituted to avoid medication errors.

Related Shortages

References

  1. Amphastar/IMS (written communication). November 2, 2009.
  2. Hospira Customer Service (personal communications). November 11 and 12, 2009.
  3. FDA (personal communications). August 4, 2010.

Updated

Updated August 5, 2010, by Michelle Wheeler, Pharm.D., Drug Information Specialist. Created December 16, 2009, by Erin R. Fox, Pharm.D., Manager, Drug Information Service. Copyright 2009. Drug Information Service, University of Utah, Salt Lake City, UT

Hide